[go: up one dir, main page]

KR800000304B1 - Preparation of thiazolo [3, 4-b] isoquinoline derivatives - Google Patents

Preparation of thiazolo [3, 4-b] isoquinoline derivatives Download PDF

Info

Publication number
KR800000304B1
KR800000304B1 KR7601892A KR760001892A KR800000304B1 KR 800000304 B1 KR800000304 B1 KR 800000304B1 KR 7601892 A KR7601892 A KR 7601892A KR 760001892 A KR760001892 A KR 760001892A KR 800000304 B1 KR800000304 B1 KR 800000304B1
Authority
KR
South Korea
Prior art keywords
isoquinoline
tetrahydro
hydroxymethyl
thiazolo
pyrid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
KR7601892A
Other languages
Korean (ko)
Inventor
화아제 다니엘
죠신 아란
폰시네 제라아
레이스돌프 다니엘
Original Assignee
엠 허어슨
로오느-푸우랜크 인더스트리이즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엠 허어슨, 로오느-푸우랜크 인더스트리이즈 filed Critical 엠 허어슨
Priority to KR7601892A priority Critical patent/KR800000304B1/en
Application granted granted Critical
Publication of KR800000304B1 publication Critical patent/KR800000304B1/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

내용 없음.No content.

Description

티아졸로[3, 4-b] 이소퀴놀린 유도체의 제법Preparation of thiazolo [3, 4-b] isoquinoline derivatives

본 발명은 치료제로서 유용한 다음 일반식(I)로 표시된 티아졸로[3, 4-b] 이소퀴놀린 유도체 및 그 산부가염의 신규 제조방법에 관한 것이다.The present invention relates to thiazolo [3,4-b] isoquinoline derivatives represented by the following general formula (I) and useful methods for preparing acid addition salts thereof useful as therapeutic agents.

Figure kpo00001
Figure kpo00001

식중,Food,

A는 3-피리딜기 및 5-이소퀴놀릴기를 표시하며 Ar가 3-피리딜기일때,A represents a 3-pyridyl group and a 5-isoquinolyl group, and when Ar is a 3-pyridyl group,

X1는 수소원자나 할로겐원자를 표시하며,X 1 represents a hydrogen atom or a halogen atom,

X2는 수소 또는 불소원자를 표시하고,X 2 represents hydrogen or fluorine atom,

X3는 수소원자 또는 니트로기를 표시하며,X 3 represents a hydrogen atom or a nitro group,

X1, X2및 X3중의 적어도 2개는 수소원자를 표시하고, 또는 X1및 X2는 함께 메틸렌 디옥시기를 표시하고At least two of X 1 , X 2 and X 3 represent a hydrogen atom, or X 1 and X 2 together represent a methylene dioxy group and

X3는 수소원자를 표시한다.X 3 represents a hydrogen atom.

A가 5-이소퀴놀릴기를 표시할 경우When A represents 5-isoquinolyl group

X, X2및 X3는 각각 수소원자를 표시한다.X, X 2 and X 3 each represent a hydrogen atom.

일반식(I)의 화합물은(R)-형 및(S)-형으로 존재할 수 있으며 본 발명은 이러한 두 형태의 화합물과 이들 혼합물을 모두 포함한다.Compounds of formula (I) may exist in (R) -form and (S) -form and the present invention includes both these types of compounds and mixtures thereof.

본 발명에 의하면 일반식(l)의 티아졸로[3,4-b] 이소퀴놀린 유도체는 다음 일반식(Ⅱ)로 표시된 1, 2, 3, 4-테트라하이드로 이소퀴놀린 유도체를 환화시켜 제조한다.According to the present invention, the thiazolo [3,4-b] isoquinoline derivative of the general formula (l) is prepared by cyclizing the 1, 2, 3, 4-tetrahydro isoquinoline derivative represented by the following general formula (II).

Figure kpo00002
Figure kpo00002

식중,Food,

A1은 3-피리딜 또는 5-이소퀴놀릴기를 표시하고,A 1 represents a 3-pyridyl or 5-isoquinolyl group,

A1이 3-피리딜기를 표시할 경우,When A 1 represents a 3-pyridyl group,

X4는 수소 또는 할로겐원자를 표시하며,X 4 represents hydrogen or a halogen atom,

X5는 수소 또는 불소원자를 표시하고,X 5 represents hydrogen or fluorine atom,

X6는 수소원자 또는 니트로기를 표시하며,X 6 represents a hydrogen atom or a nitro group,

X4, X5및 X6중의 적어도 2개는 수소원자를 표시하거나,At least two of X 4 , X 5 and X 6 represent a hydrogen atom, or

X4및 X5는 함께 메틸렌디옥시기를 표시하고,X 4 and X 5 together represent a methylenedioxy group,

X6는 수소원자를 표시하는 한편,X 6 represents a hydrogen atom,

A1이 5-이소퀴놀릴기를 표시할 경우,When A 1 represents a 5-isoquinolyl group,

X4, X5및 X6는 수소원자를 표시한다.X 4 , X 5 and X 6 represent a hydrogen atom.

반응은 일반적으로 산매체중에서 가열하여 실시한다. 특히 반응은 무기산수용액, 예컨대 염산수용액중에서 65-100℃ 범위의 온도에서 실시하는 것이 유리하다.The reaction is generally carried out by heating in an acid medium. In particular, the reaction is advantageously carried out in an aqueous inorganic acid solution such as aqueous hydrochloric acid at a temperature in the range of 65-100 ° C.

일반식(Ⅱ)의 1, 2, 3, 4-테트라하이드로 이소퀴놀린 유도체는 다음 일반식(Ⅲ)의 이소티오시아네이트를 다음 일반식(Ⅳ)의 3-하이드록시 메틸-1, 2, 3, 4-테트라하이드로 이소퀴놀린 유도체와 반응시켜 제조할 수 있다.1, 2, 3, 4-tetrahydro isoquinoline derivatives of the general formula (II) is the following isothiocyanate of the general formula (III) and 3-hydroxy methyl-1, 2, 3 of the general formula (IV) And 4-tetrahydro isoquinoline derivatives.

Figure kpo00003
Figure kpo00003

식중,Food,

A1, X4, X5및 X6는 상술한 바와같다.A 1 , X 4 , X 5 and X 6 are as described above.

반응은 일반적으로 15-70℃ 범위의 온도에서 알콜, 예컨대 에탄올과 같은 유기용매중에서 실시한다.The reaction is generally carried out in organic solvents such as alcohols such as ethanol at temperatures in the range of 15-70 ° C.

일반식(Ⅲ)에서 A1이 5-이소퀴놀릴기를 표시하는 일반식(Ⅲ)의 이소티오시아네이트는 이황화탄소와 5-아미노 이소퀴놀린과를 축합시킨 다음에 디싸이클로헥실카보디이미드를 첨가하여 제조할 수 있다. 축합은 일반적으로 3급 아민, 예컨대 트리에틸아민과 같은 염기의 존재하에 실시한다. 반응은 -10℃내지 25℃ 범위의 온도에서 피리딘과 같은 유기용매중에서 실시하는 것이 유리하다.In general formula (III), isothiocyanate of general formula (III) in which A 1 represents a 5-isoquinolyl group is condensed with carbon disulfide and 5-amino isoquinoline, and then dicyclohexylcarbodiimide is added. Can be prepared. Condensation is generally carried out in the presence of a base such as a tertiary amine such as triethylamine. The reaction is advantageously carried out in an organic solvent such as pyridine at a temperature in the range of −10 ° C. to 25 ° C.

일반식(Ⅳ)의 3-하이드록시메틸-1, 2, 3, 4-테트라하이드로 이소퀴놀린 유도체는 다음 일반식(Ⅴ)의 1, 2, 3, 4-테트라하이드로 이소퀴놀린 유도체 또는 그 산부가염을 환원시켜 제조할 수 있다.3-hydroxymethyl-1, 2, 3, 4-tetrahydro isoquinoline derivatives of the general formula (IV) are 1, 2, 3, 4-tetrahydro isoquinoline derivatives of the following general formula (V) or acid addition salts thereof It can be prepared by reducing.

Figure kpo00004
Figure kpo00004

식중,Food,

R는 수소원자 또는 탄소원자수 1-4개의 알킬기를 표시하고,R represents a hydrogen atom or an alkyl group of 1-4 carbon atoms,

X4, X5및 X6는 상술한 바와같다.X 4 , X 5 and X 6 are as described above.

일반식(V)에서 R가 수소원자를 표시하는 경우, 환원은 20-70℃ 범위의 온도에서 테트라하이드로푸란중에서 리티움 알루미늄 하이드라이드를 사용하여 행하는 것이 좋다.When R represents a hydrogen atom in the general formula (V), the reduction is preferably performed using lithium aluminum hydride in tetrahydrofuran at a temperature in the range of 20-70 ° C.

일반식(V)에서 R가 탄소원자수 1-4개의 알킬기를 표시하는 경우, 환원은 유기용매 또는 에탄올-물혼합물과 같은 수용성 유기매체중에서 10℃내지 반응혼합물의 환류온도 범위의 온도에서 소디움 보로하이드라이드와 같은 알카리금속 보로하이드라이드를 사용하여 행하는 것이 좋다.When R in formula (V) represents an alkyl group of 1-4 carbon atoms, the reduction is sodium borohydride at temperatures ranging from 10 ° C. to the reflux temperature of the reaction mixture in an aqueous solvent such as an organic solvent or an ethanol-water mixture. It is preferable to use an alkali metal borohydride such as a ride.

식중 X6가 니트로기를 표시하는 일반식(Ⅳ)의 화합물이 필요한 경우에는 일반식(V)의 에스테르(R=알킬)를 사용하는 것이 좋다. 이 경우 환원은 니트로기에 아무 영향을 끼치지 않는 조건하에 일어난다.When a compound of the general formula (IV) in which X 6 represents a nitro group is required, it is preferable to use an ester of the general formula (V) (R = alkyl). In this case the reduction takes place under conditions which have no effect on the nitro group.

식중 R가 탄소원자수 1-4개의 알킬기를 표시하는 일반식(V)의 1, 2, 3, 4-테트라하이드로 이소퀴놀린유도체는 분자의 잔여기에 영향없이, 산을 에스테르로 전환시키는 공지의 방법에 의하여 R가 수소원자인 일반식(V)의 1, 2, 3, 4-테트라하이드로 이소퀴놀린 유도체를 에스테르화하여 제조할 수 있다.Formula 1, 2, 3, 4-tetrahydro isoquinoline derivatives of general formula (V), wherein R represents an alkyl group having 1-4 carbon atoms, are known in a known method for converting acids to esters without affecting the remaining groups of the molecule. It can be prepared by esterifying 1, 2, 3, 4-tetrahydro isoquinoline derivative of the general formula (V) wherein R is a hydrogen atom.

본 명세서 및 특허청구범위에서 사용된 ''공지방법''이라함은 종래에 사용되였거나 화학문헌에 기술된 방법을 의미한다.As used herein and in the claims, the term `` notice method '' means a method that has been used conventionally or described in the chemical literature.

식중, R가 수소원자를 표시하고 X4및 X5가 상술한 바와 같으며 X6가 수소원자를 표시하는 일반식(V)의 1, 2, 3, 4-테트라하이드로 이소퀴놀린 유도체는 Chem. Ber., 44, 2, 030(1911)에 피크테트(A. Pictet) 및 스핑글러(Th. Spengler)에 의해 발표된 방법을 이용하여 다음 일반식(Ⅵ)의 페닐아라닌 유도체로부터 제조할 수 있다.Wherein 1, 2, 3, 4-tetrahydro isoquinoline derivatives of general formula (V) wherein R represents a hydrogen atom, X 4 and X 5 are as described above, and X 6 represents a hydrogen atom, are described in Chem. Ber., 44, 2, 030 (1911) can be prepared from phenylalanine derivatives of the following general formula (VI) using a method published by A. Pictet and Th. Spengler. Can be.

Figure kpo00005
Figure kpo00005

식중,Food,

X4및 X5는 상술한 바와같다.X 4 and X 5 are as described above.

일반식(Ⅵ)으로 표시된 페닐아라닌 유도체의 (L)-형이 사용될 때 일반식(Ⅴ)의 화합물을 거쳐서 얻어지는 일반식(I)의 화합물은 (S)-형이다. 일반식(Ⅵ)으로 표시된 페닐아라닌 유도체가 (D)-형으로 사용될때 일반식(I)의 화합물은 (R)-형으로 얻어진다. 일반식(Ⅵ)으로 표시된 페닐아라닌 유도체의 (D)-형과 (L)-형의 혼합물로 사용될 때 얼반식(I)의 화합물은 (R, S)-형으로 얻어진다.When the (L) -form of the phenylalanine derivative represented by formula (VI) is used, the compound of formula (I) obtained via the compound of formula (V) is (S) -form. When the phenylalanine derivative represented by the general formula (VI) is used in the (D) -form, the compound of the general formula (I) is obtained in the (R) -form. When used as a mixture of the (D) -form and the (L) -form of the phenylalanine derivative represented by the general formula (VI), the compound of the formula (I) is obtained in the (R, S) -form.

식중 X6가 니트로기를 표시하는 일반식(Ⅱ), (Ⅳ) 및 (V)의 화합물은 식중 X6가 수소원자인 일반식(Ⅱ)(Ⅳ) 및 (V)의 화합물을 니트로화하여 제조할 수 있다.The compounds of formulas (II), (IV) and (V) in which X 6 represents a nitro group are prepared by nitrating the compounds of formulas (II) (IV) and (V) in which X 6 represents a hydrogen atom. can do.

니트로화 반응은 일반적으로 약 -20℃의 온도에서 질산과 황산의 혼합물을 사용하거나 약 20℃의 온도에서 질산나트륨과 트리플루오로초산의 혼합물을 사용하여 실시하고, 이어서 필요에 따라 얻어진 이성체를 분리시킨다.The nitration reaction is generally carried out using a mixture of nitric acid and sulfuric acid at a temperature of about −20 ° C. or a mixture of sodium nitrate and trifluoroacetic acid at a temperature of about 20 ° C., then separating the isomers obtained as necessary. Let's do it.

상술한 방법으로 얻어진 일반식(I)의 티아졸로[3,4-b] 이소퀴놀린 유도체는 결정법 또는 크로마토그래피와 같은 물리적 방법에 의해 정제하던가, 또는 염형성법, 염의 결정화법 및 알카리성 매체중에서 염류의 분해법과 같은 화학적 방법에 의해 정제할 수 있다. 이 화학적 방법을 실시하는 경우 염의 음이온성질은 중요하지 않으며, 유일한 필수조건은 염이 잘 형성되어서 결정화가 용이해야 한다는 점이다.The thiazolo [3,4-b] isoquinoline derivatives of the general formula (I) obtained by the above-described methods may be purified by physical methods such as crystallization or chromatography, or salt formation, salt crystallization and salting in alkaline media. It can refine | purify by chemical methods, such as a decomposition method. The anionic nature of the salt is not critical when this chemical method is carried out, and the only prerequisite is that the salt is well formed and easy to crystallize.

일반식(I)의 티아졸로[3,4-b] 이소퀴놀린 유도체는 공지의 방법에 의해 산부가염으로 전환될 수 있다. 산부가염은 적당한 용매중에서 티아졸로[3,4-b] 유도체에 산을 작용시켜 얻는다. 유기용매로서는 알콜, 케톤, 에테르 또는 염소화된 탄화수소등이 사용된다. 형성되는 염은 필요에 따라 용액을 농축시킨후 침전시켜 여과하거나 기울여서 배수하여 분리한다.The thiazolo [3,4-b] isoquinoline derivatives of formula (I) can be converted to acid addition salts by known methods. Acid addition salts are obtained by reacting an acid with a thiazolo [3,4-b] derivative in a suitable solvent. As the organic solvent, alcohols, ketones, ethers or chlorinated hydrocarbons are used. The salts formed are separated by concentration of the solution, precipitated, filtered or tilted and drained as necessary.

일반식(I)의 티아졸로[3,4-b] 이소퀴놀린 유도체 및 그 산부가염은 유용한 약물학적 성질을 가지고 있다. 특히 일반식(I)의 화합물과 그 산부가염은 진통제 및 해열제로서 유효하며 항염증 작용을 약간 나타낸다.Thiazolo [3,4-b] isoquinoline derivatives of formula (I) and acid addition salts thereof have useful pharmacological properties. In particular, the compound of formula (I) and acid addition salts thereof are effective as analgesics and antipyretics, and have some anti-inflammatory action.

일반식(I)의 화합물과 그 산부가염은 Proc. Soc. Exp. Biol. Med., 137, 536(1971)에서 K. F. Swingle-et al.,에 의해 개량발표된 Arch. Int. Pharmacodyn., 111, 409(1957)에 발표된 L. O. Randall 및 J. J. Selitto의 기술에 따라 쥐에게 경구투여시 2-50mg/kg의 용량으로 진통제로서 유효함이 입증되었다. 또한 일반식(I)로 표시된 유도체의 대부분은 Proc. Soc. Exp. Biol. Med, 95, 729(1957)에 발표된 E. Siegmund의 기술에 따라 생쥐에게 경구투여시 20-200mg/kg의 용량으로 유효함이 입증되었다.Compounds of formula (I) and acid addition salts thereof are prepared according to Proc. Soc. Exp. Biol. Arch., Improved by K. F. Swingle- et al., In Med., 137, 536 (1971). Int. The techniques of L. O. Randall and J. J. Selitto, published in Pharmacodyn., 111, 409 (1957), have proven effective as analgesics at doses of 2-50 mg / kg when administered orally to rats. In addition, most of the derivatives represented by the general formula (I) are proc. Soc. Exp. Biol. E. Siegmund's technique, published in Med, 95, 729 (1957), has proven effective at doses of 20-200 mg / kg when administered orally to mice.

일반식(I)로 표시된 티아졸로[3,4-b] 이소퀴놀린 유도체의 해열작용은 Toxicol. Appl. Pharmacol., 22, 674(1972)에 발표된 J. J. Loux et al.의 기술에 따라 생쥐에게 경구투여시 5-50mg/kg의 용량으로 입증되었다.The antipyretic effect of thiazolo [3,4-b] isoquinoline derivatives represented by formula (I) is shown in Toxicol. Appl. According to the technique of J. J. Loux et al., Published in Pharmacol., 22, 674 (1972), a dose of 5-50 mg / kg was orally administered to mice.

항염증작용은 Arch. Int. Pharmacodyn., 144, 185(1963)에 발표된 K. F. Benitz 및 L. M. Hall와 기술에 따라 쥐에게 경구투여시 5-50mg/kg의 용량에서 유도체의 대부분에서 입증되었다. 이외에 일반식(I)의 티아졸로[3, 4-b] 이소퀴놀린 유도체는 독성이 적으며, LD50은 300mg/kg내지 3,000mg/kg 범위이다.Anti-inflammatory action is Arch. Int. According to KF Benitz and LM Hall and the technique, published in Pharmacodyn., 144, 185 (1963), it was demonstrated in most of the derivatives at doses of 5-50 mg / kg upon oral administration to rats. In addition, thiazolo [3,4-b] isoquinoline derivatives of formula (I) are less toxic and LD 50 ranges from 300 mg / kg to 3,000 mg / kg.

일반식(I)의 화합물중에서 특히 중요한 것은 식중 A가 3-피리딜, 또는 5-이소퀴놀릴기를 표시하고, X1, X2및 X3가 수소원자를 표시하는 (R)-및 (S)-형 티아졸로[3, 4-b] 이소퀴놀린 유도체와 이를 혼합물 및 산부가염이며, 더욱 상세히 말하면 (S)-3-(피리드-3-일이미노)-1, 5, 10, 10a-테트라하이드로티아졸로[3,4-b] 이소퀴놀린, (R)-3-(피리드-3-일이미노)-1, 5, 10, 10a-테트라하이드로티아졸로[3,4-b] 이소퀴놀린, (R, S)-3-(피리드-3-일이미노) 1, 5, 10, 10a-테트라하이드로티아졸로[3, 4-b]이소퀴놀린, (S)-3-(이소퀴놀-5-일이미노)-티아졸로[3, 4-b]이소퀴놀린 및, (R)-3-(이소퀴놀-5-일이미노)-1, 5, 10, 10a-테트라하이드로 티아졸로[3,4-b] 이소퀴놀린 및 이를의 산부가염류이다.Of particular importance among the compounds of formula (I) are those in which A represents a 3-pyridyl, or 5-isoquinolyl group, and X 1 , X 2 and X 3 represent a hydrogen atom; ) -Type thiazolo [3, 4-b] isoquinoline derivatives and mixtures and acid addition salts thereof, more specifically (S) -3- (pyrid-3-ylimino) -1, 5, 10, 10a -Tetrahydrothiazolo [3,4-b] isoquinoline, (R) -3- (pyrid-3-ylimino) -1,5,10,10a-tetrahydrothiazolo [3,4-b Isoquinoline, (R, S) -3- (pyrid-3-ylimino) 1, 5, 10, 10a-tetrahydrothiazolo [3, 4-b] isoquinoline, (S) -3- (Isoquinol-5-ylimino) -thiazolo [3, 4-b] isoquinoline and (R) -3- (isoquinol-5-ylimino) -1, 5, 10, 10a-tetra Hydrothiazolo [3,4-b] isoquinoline and acid addition salts thereof.

일반식(I)의 티아졸로[3,4-b] 이소퀴놀린 유도체는 치료목적으로서 그대로 사용하거나 무독성 산부가염의 형태, 예컨대 염기의 고유하고 유익한 생리적 성질이 음이온에 기인하는 부작용에 의해 무효화되지 않도록 염류(염산염, 황산염, 질산염, 인산염, 초산염, 프로피온산염, 썩신산염, 벤조산염, 푸마르산염, 말레산염, 주석산염, 테오필린초산염, 쌀리실산염, 페놀프탈레인산염, 및 메틸렌-비스-β-하이드록시나프토에이트등)의 치료 용량으로, 동물 유기체에 비교적 무해한 음이온을 함유한 염류의 형태로 사용된다.Thiazolo [3,4-b] isoquinoline derivatives of formula (I) may be used as such for therapeutic purposes or in the form of nontoxic acid addition salts such that the inherent and beneficial physiological properties of the bases are not countered by adverse effects caused by anions. Salts (hydrochlorides, sulfates, nitrates, phosphates, acetates, propionates, succinates, benzoates, fumarates, maleates, tartarates, theophylline acetates, riceicylates, phenolphthaleins, and methylene-bis-β-hydroxynaphs Toe, etc.), in the form of salts containing anions that are relatively harmless to animal organisms.

이하 실시예에 의하여 본 발명을 상세히 설명하면 다음과 같다.Hereinafter, the present invention will be described in detail with reference to the following examples.

[실시예 1]Example 1

(S)-3-하이드록시메틸-N-피리드-3-일)-1,2,3,4-테트라하이드로이소퀴놀린-2-카보티오아미드(13.5g)을 100℃에서 40분간 가열하여 냉각시킨 후 얻어진 용액을 1/5의 용량으로 되게 감압(25mmHg)하에 농축시키고 10N 수산화나트륨용액(200cc)을 첨가하여 알카리성화시켜 메틸렌클로라이드(3×150cc)로 추출한다음, 유기추출액을 합쳐 황산마그네슘상에서 건조후 여과하여 여액을 감압(25mmHg)하에 농축건조하여 황색 유상물을 얻고, 이 유상물에 디이소프로필 에테르(150cc)를 가하여 석출된 백색침전을 여과분리한 후 이 침전을 디이소프로필 에테르(3×10cc)로 세척하여 60℃에서 감압(1mmHg)하에 건조시킨 결과 (S)-3-(피리드-3-일이미노)-1, 5, 10, 10a-테트라하이드로 티아졸로[3, 4-b] 이소퀴놀린(9.8g)이 얻어졌다. 융점 111℃(S) -3-hydroxymethyl-N-pyrid-3-yl) -1,2,3,4-tetrahydroisoquinoline-2-carbothioamide (13.5 g) was heated at 100 ° C. for 40 minutes After cooling, the resulting solution was concentrated under reduced pressure (25mmHg) to a capacity of 1/5, alkalinized by adding 10N sodium hydroxide solution (200cc), extracted with methylene chloride (3 × 150cc), and the organic extracts were combined with magnesium sulfate. After drying over filtration, the filtrate was concentrated to dryness under reduced pressure (25mmHg) to give a yellow oily substance. Diisopropyl ether (150cc) was added to the oily substance, and the precipitated white precipitate was collected by filtration. Washed with (3 × 10 cc) and dried under reduced pressure (1 mmHg) at 60 ° C. (S) -3- (pyrid-3-ylimino) -1,5,10,10a-tetrahydro thiazolo [3 , 4-b] isoquinoline (9.8 g) was obtained. Melting point 111 ℃

Figure kpo00006
= -258±3°(C=2, 에탄올)
Figure kpo00006
= -258 ± 3 ° (C = 2, ethanol)

출발물질로서 사용된 (S)-3-하이드록시메틸-N-(피리드-3-일)-1,2,3,4-테트라하이드로 이소퀴놀린-2-카보티오이미드의 제법은 다음과 같다.The preparation of (S) -3-hydroxymethyl-N- (pyrid-3-yl) -1,2,3,4-tetrahydro isoquinoline-2-carbothioimide used as starting material is as follows. .

에탄올(150cc)에 용해시킨 (S)-3-하이드록시메틸-1,2,3,4-테트라하이드로이소퀴놀린(8.15g)의 용액에 3-이소티오시아나토피리딘(6.8g)을 가하고 약 20℃의 온도에서 3시간후에 용액을 0℃로 냉각하여 석출된 백색 침전을 여과 분리하여 프로판올(200cc)로부터 재결정시킨 다음, 결정을 여과하여 프로판올(2×10cc)로 세척한 후 60℃에서 감압(1mmHg)하에 건조시킨 결과 (S)-3-하이드록시메틸-N-(피리드-3-일)-1,2,3,4-테트라하이드로 이소퀴놀린-2-카보티오아미드(12.1g)가 얻어쳤다. 융점 192℃To a solution of (S) -3-hydroxymethyl-1,2,3,4-tetrahydroisoquinoline (8.15 g) dissolved in ethanol (150 cc) was added 3-isothiocyanatopyridine (6.8 g) and After 3 hours at 20 ° C., the solution was cooled to 0 ° C., and the precipitated white precipitate was separated by filtration and recrystallized from propanol (200 cc). The crystals were filtered off, washed with propanol (2 × 10 cc), and then reduced at 60 ° C. (S) -3-hydroxymethyl-N- (pyrid-3-yl) -1,2,3,4-tetrahydro isoquinoline-2-carbothioamide (12.1 g) as a result of drying under (1 mmHg) Got it. Melting point 192 ℃

Figure kpo00007
= +55±1°(C =1, 디메틸포름아미드)
Figure kpo00007
= + 55 ± 1 ° (C = 1, dimethylformamide)

(S)-3-하이드록시메틸-1,2,3,4-테트라하이드로 이소퀴놀린은 Chem. Pharm. Bull., 15, 490(1967)에 발표된 S. Yamada 및 T. Kunieda의 방법에 따라 제조할 수 있다.(S) -3-hydroxymethyl-1,2,3,4-tetrahydro isoquinoline is obtained from Chem. Pharm. It may be prepared according to the methods of S. Yamada and T. Kunieda published in Bull., 15, 490 (1967).

3-이소티오시아나토피리딘은 Chem. Ber, 101, 1, 746(1968)에 발표된 J. C. Jochims의 방법에 따라 제조할 수 있다.3-isothiocyanatopyridine is described in Chem. It may be prepared according to the method of J. C. Jochims published in Ber, 101, 1, 746 (1968).

[실시예 2]Example 2

실시예 1의 방법에 따라 출발물질로서 6N 염산(150cc)에 용해시킨 (R)-3-하이드록시메틸-N-(피리드-3-일)-1,2,3,4-테트라하이드로 이소퀴놀린-2-카보티오아미드(12g)를 사용한 결과 (R)-3-(피리드-3-일이미노)-1,5,10,10a-테트라하이드로티아졸로[3, 4-b] 이소퀴놀린(6.8g)이 얻어졌다.(R) -3-hydroxymethyl-N- (pyrid-3-yl) -1,2,3,4-tetrahydroisoiso dissolved in 6N hydrochloric acid (150 cc) as a starting material according to the method of Example 1 Results from using quinoline-2-carbothioamide (12 g) (R) -3- (pyrid-3-ylimino) -1,5,10,10a-tetrahydrothiazolo [3,4-b] iso Quinoline (6.8 g) was obtained.

융점 112℃Melting point 112 ℃

Figure kpo00008
=+260±3°(C =2, 에탄올)
Figure kpo00008
= +260 ± 3 ° (C = 2, ethanol)

출발물질로서 사용된 (R)-3-하이드록시메틸-N-(피리드-3-일)-1,2,3,4-테트라하이드로 이소퀴놀린-2-카보티오아미드(융점 196℃

Figure kpo00009
=-55±1°(C=2, 디메틸포름아미드)]는 실시예 1에 기술된 조건으로 처리하여 (R)-3-하이드록시메틸-1, 2, 3, 4-테트라하이드로 이소퀴놀린으로부터 제조할 수 있다.(R) -3-hydroxymethyl-N- (pyrid-3-yl) -1,2,3,4-tetrahydro isoquinoline-2-carbothioamide (melting point 196 ° C) used as starting material
Figure kpo00009
= -55 ± 1 ° (C = 2, dimethylformamide)] was treated from (R) -3-hydroxymethyl-1, 2, 3, 4-tetrahydro isoquinoline by treatment under the conditions described in Example 1. It can manufacture.

(R)-3-하이드록시메틸-1,2,3,4-테트라하이드로 이소퀴놀린[융점 116℃

Figure kpo00010
=+94±1°(C =2, 에탄올)]은 Chem. Pharm. Bull. 15, 490(1967)에서 L-페닐아라닌에 대해 발표된 S. Yamada 및 T. Kunieda의 방법에 따라 L-페닐아라닌으로부터 제조할 수 있다.(R) -3-hydroxymethyl-1,2,3,4-tetrahydro isoquinoline [melting point 116 ° C
Figure kpo00010
= + 94 ± 1 ° (C = 2, ethanol)]. Pharm. Bull. 15, 490 (1967) can be prepared from L-phenylalanine according to the methods of S. Yamada and T. Kunieda published for L-phenylalanine.

[실시예 3]Example 3

실시예 1의 방법에 따라 출발물질로서 6N 염산(1.4ℓ)에 용해시킨 (R, S)-3-하이드록시메틸-N-(피리드-3-일)-1, 2, 3, 4-테트라하이드로 이소퀴놀린-2-카보티오아미드(115g)을 사용한 결과 (R, S)-3-(피리드-3-일이미노)-1, 5, 10, 10a-테트라하이드로 티아졸로[3, 4-b]이소퀴놀린(76g)이 얻어졌다. 융점 110℃(R, S) -3-hydroxymethyl-N- (pyrid-3-yl) -1, 2, 3, 4- dissolved in 6N hydrochloric acid (1.4 L) as a starting material according to the method of Example 1 As a result of using tetrahydro isoquinoline-2-carbothioamide (115 g) (R, S) -3- (pyrid-3-ylimino) -1, 5, 10, 10a-tetrahydro thiazolo [3, 4-b] isoquinoline (76 g) was obtained. Melting point 110 ℃

출발물질로서 사용된 (R, S)-3-하이드록시메틸-N-(피리드-3-일)-1, 2, 3, 4-테트라하이드로 이소퀴놀린-2-카보티오아미드(즉시 융점; 180℃)는 (S)-3-하이드록시메틸-N-(피리드-3-일)-1,2,3,4-테트라하이드로 이소퀴놀린-2-카보티오아미드의 제조를 위한 실시예 1에 기술된 조건으로 처리하여(R, S)-3-하이드록시메틸-1, 2, 3, 4-데트라하이드로 이소퀴놀린으로부터 제조할 수 있다.(R, S) -3-hydroxymethyl-N- (pyrid-3-yl) -1, 2, 3, 4-tetrahydro isoquinoline-2-carbothioamide (immediate melting point) used as starting material; 180 ° C.) is Example 1 for the preparation of (S) -3-hydroxymethyl-N- (pyrid-3-yl) -1,2,3,4-tetrahydro isoquinoline-2-carbothioamide It can be prepared from (R, S) -3-hydroxymethyl-1, 2, 3, 4-detrahydro isoquinoline by treatment under the conditions described in.

(R, S)-3-하이드록시메틸-1, 2, 3, 4-테트라하이드로 이소퀴놀린은 Med. Pharm. Chem. 4, 79(1961)에 발표된 E. Schipper et al.의 방법에 따라 DL-페닐아라닌으로부터 제조할 수 있다.(R, S) -3-hydroxymethyl-1, 2, 3, 4-tetrahydro isoquinoline is Med. Pharm. Chem. 4, 79 (1961), can be prepared from DL-phenylalanine according to the method of E. Schipper et al.

[실시예 4]Example 4

(R, S)-6-플루오로-3-하이드록시메틸-N-(피리드-3-일)-1, 2, 3, 4-테트라하이드로 이소퀴놀린-2-카보티오아미드(19g) 및 6N 염산(240cc)을 65℃에서 1시간동안 가열한 후 반응혼합물을 0℃로 냉각시키고 10N 수산화나트륨 용액을 가하여 알카리성화 시킨다음, 혼합물을 메틸렌 클로라이드(총 450cc)로 3회 추출하여 유기층을 황산나트륨상에서 건조시킨 후 여과하여 40℃에서 감압(25mmHg)에 농축건조시켜 얻어진 잔사를 아세토니트릴로부터 재결정시킨 결과 (R, S)-8-플루오로-3-(피리드-3-일이미노)-1, 5, 10, 10a-테트라하이드로 티아졸로[3, 4-b] 이소퀴놀린(14g)이 얻어졌다. 융점 139℃(R, S) -6-fluoro-3-hydroxymethyl-N- (pyrid-3-yl) -1, 2, 3, 4-tetrahydro isoquinoline-2-carbothioamide (19 g) and After 6N hydrochloric acid (240cc) was heated at 65 ° C for 1 hour, the reaction mixture was cooled to 0 ° C and alkalinized by the addition of 10N sodium hydroxide solution. The mixture was extracted three times with methylene chloride (450cc in total), and the organic layer was sodium sulfate. After drying over, filtered and concentrated to dryness under reduced pressure (25mmHg) at 40 ° C, the residue was recrystallized from acetonitrile (R, S) -8-fluoro-3- (pyrid-3-ylimino)- 1, 5, 10, 10a-tetrahydro thiazolo [3, 4-b] isoquinoline (14 g) was obtained. Melting point 139 ℃

출발물질로서 사용된 (R, S)-6-플루오로-3-하이드록시메틸-N-(피리드-3-일)-1, 2, 3, 4-테트라하이드로 이소퀴놀린-2-카보티오아미드의 제법은 다음과 같다.(R, S) -6-fluoro-3-hydroxymethyl-N- (pyrid-3-yl) -1, 2, 3, 4-tetrahydro isoquinoline-2-carbothio used as starting material The manufacturing method of an amide is as follows.

에탄올(250cc)에 용해시킨 (R, S)-6-플루오로-3-하이드록시메틸-1, 2, 3, 4-테트라하이드로 이소퀴놀린(20g)의 용액에 3-이소티오시아나토피리딘(15g)을 약 15℃에서 5분간에 걸쳐 가하면 온도가 점차적으로 상승하며 백색침전이 형성되는바, 혼합물을 20℃에서 20시간동안 교반한 후 침전을 여과 분리하여 디에틸 에테르(40cc)로 세척, 건조시키면 (R, S)-6-플루오로-3-하이드록시메틸-N-(피리드-3-일)-1, 2, 3, 4-테트라하이드로 이소퀴놀린-2-카보티오아미드(34g)가 백색결정의 형태로 얻어진다. 융점 190℃3-isothiocyanatopyridine (20 g) in a solution of (R, S) -6-fluoro-3-hydroxymethyl-1, 2, 3, 4-tetrahydro isoquinoline (20 g) dissolved in ethanol (250 cc) 15 g) was added at about 15 ° C. over 5 minutes, the temperature gradually increased and white precipitate was formed. The mixture was stirred at 20 ° C. for 20 hours, and the precipitate was filtered off and washed with diethyl ether (40 cc). Drying results in (R, S) -6-fluoro-3-hydroxymethyl-N- (pyrid-3-yl) -1, 2, 3, 4-tetrahydro isoquinoline-2-carbothioamide (34 g ) Is obtained in the form of white crystals. Melting point 190 ℃

(R, S)-3-플루오로-3-하이드록시메틸-1, 2, 3, 4-테트라하이드로 이소퀴놀린의 제법은 다음과 같다.The preparation method of (R, S) -3-fluoro-3-hydroxymethyl-1, 2, 3, 4-tetrahydro isoquinoline is as follows.

물(280cc)과 에탄올(280cc)에 용해시킨 소디움 보로하이드라이드(46g)을 물(280cc)과 에탄올(280cc)에 용해시킨 (R, S)-3-에톡시카보닐-6-플루오로-1, 2, 3, 4-테트라하이드로 이소퀴놀린 염산염(79g)에 가하고, 반응혼합물을 약 20℃에서 20시간동안 교반한 후 혼합물을 40℃에서 감압(25mmHg)하에 농축건조하고 잔사를 물(500cc)에 용해시켜 메틸렌클로하이드(총500cc)로 3회 추출한다음, 소량의 불용성물질을 여과제거하고 유기층을 황산나트륨 상에서 건조, 여과하여 40℃에서 감압(25mmHg)하에 농축건조시킨후 잔사를 아세토니트릴로부터 재결정시키면 (R, S)-6-플루오로-3-하이드록시메틸-1, 2, 3, 4-테트라하이드로 이소퀴놀린(27g)이 백색결정의 형태로 얻어진다. 융점 121℃Sodium borohydride (46 g) dissolved in water (280 cc) and ethanol (280 cc) was dissolved in water (280 cc) and ethanol (280 cc) (R, S) -3-ethoxycarbonyl-6-fluoro- 1, 2, 3, 4-tetrahydro isoquinoline hydrochloride (79 g) was added, the reaction mixture was stirred at about 20 ° C. for 20 hours, the mixture was concentrated to dryness at 40 ° C. under reduced pressure (25 mmHg), and the residue was water (500 cc). ), Extracted three times with methylene chloride (500 cc total), and then a small amount of insoluble material was filtered off, and the organic layer was dried over sodium sulfate, filtered and concentrated to dryness at 40 ° C. under reduced pressure (25 mmHg), and then the residue was purified from acetonitrile. Recrystallization gives (R, S) -6-fluoro-3-hydroxymethyl-1, 2, 3, 4-tetrahydro isoquinoline (27 g) in the form of white crystals. Melting point 121 ℃

(R, S)-3-에톡시카보닐-6-플루오로-1, 2, 3, 4-테트라하이드로 이소퀴놀린의 염산염은 일본특허공보 제73/07, 115호에 발표된 방법에 따라 제조할 수 있다.Hydrochlorides of (R, S) -3-ethoxycarbonyl-6-fluoro-1, 2, 3, 4-tetrahydro isoquinoline are prepared according to the method disclosed in Japanese Patent Publication No. 73/07, 115 can do.

[실시예 5]Example 5

(R, S)-6, 7-메틸렌디옥시-3-하이드록시메틸-N-(피리드-3-일)-1, 2, 3, 4-테트라하이드로 이소퀴놀린-2-카보티오아미드(33.6g) 및 6N 염산(336cc)을 100℃에서 90분간 가열하고, 반응혼합물을 0℃로 냉각시켜 탄산칼리움으로 알카리성화시킨 후 메틸렌클로라이드(5×500cc)로 추출하고. 황색불용성 물질을 여과분리하여 합친 유기 추출액을 무수탄산칼리움상에서 건조시킨 다음에 40℃에서 감압(25mmHg)하에 농축 건조시키고 이때 얻어진 결정(융점 191℃)을 아세토니트릴과 디메틸포름아미드(7 : 1)의 혼합물로부터 2회 재결정시키면(R, S)-7, 8-메틸렌디옥시-3-(피리드-3-일이미노)-1 ,5, 10, 10a-테트라하이드로 티아졸로[3,4-b] 이소퀴놀린(4.5g)이 담황색 결정의 형태로 얻어진다. 융점 201℃(R, S) -6, 7-methylenedioxy-3-hydroxymethyl-N- (pyrid-3-yl) -1, 2, 3, 4-tetrahydro isoquinoline-2-carbothioamide ( 33.6 g) and 6N hydrochloric acid (336 cc) were heated at 100 ° C. for 90 minutes, the reaction mixture was cooled to 0 ° C., alkalized with calcium carbonate, and extracted with methylene chloride (5 × 500 cc). The yellow insoluble matter was separated by filtration, and the combined organic extracts were dried over anhydrous calcium carbonate, concentrated to dryness at 40 ° C. under reduced pressure (25 mmHg), and the obtained crystals (melting point 191 ° C.) were acetonitrile and dimethylformamide (7: 1). Recrystallization twice from a mixture of (R, S) -7, 8-methylenedioxy-3- (pyrid-3-ylimino) -1,5, 10, 10a-tetrahydro thiazolo [3, 4-b] Isoquinoline (4.5 g) is obtained in the form of light yellow crystals. Melting point 201 ℃

출발물질로서 사용한(R, S)-6, 7-메틸렌디옥시-3-하이드록시메틸-N-(피리드-3-일)-1, 2, 3, 4-테트라하이드로 이소퀴놀린-2-카보티오아미드의 제법은 다음과 같다.(R, S) -6, 7-methylenedioxy-3-hydroxymethyl-N- (pyrid-3-yl) -1, 2, 3, 4-tetrahydro isoquinoline-2- used as starting material The manufacturing method of carbothioamide is as follows.

3-이소티오시아나토피리딘(15g)을 에탄올(400cc)에 용해시킨(R, S)-6, 7-메틸렌디옥시-3-하이드록시메틸-N-(피리드-3-일)-l, 2, 3, 4-데트라하이드로 이소퀴놀린(20.7g)의 용액에 27℃에서 수분간에 걸쳐 가한다. 이때 온도가 37℃로 상승하며 백색침전이 신속히 형성된다. 이 반응혼합물을 약 20℃의 온도에서 20시간동안 교반한 후 침전을 여과분리하면 (R, S)-6, 7-메틸렌디옥시-3-하이드록시메틸-N-(피리드-3-일)-1, 2, 3, 4-테트라하이드로 이소퀴놀린(34g)이 담황색 결정의 형태로 단리된다. 융점 212℃3-isothiocyanatopyridine (15 g) dissolved in ethanol (400 cc) (R, S) -6, 7-methylenedioxy-3-hydroxymethyl-N- (pyrid-3-yl) -l To a solution of 2, 3, 4-detrahydro isoquinoline (20.7 g) was added at 27 ° C. over several minutes. At this time, the temperature rises to 37 ° C and white precipitates are formed rapidly. The reaction mixture was stirred at a temperature of about 20 ° C. for 20 hours, and then the precipitate was separated by filtration. ) -1, 2, 3, 4-tetrahydro isoquinoline (34 g) is isolated in the form of pale yellow crystals. Melting point 212 ℃

(R, S)-6, 7-메틸렌디옥시-3-하이드록시메틸-1, 2, 3, 4-테트라하이드로 이소퀴놀린의 제법은 다음과 같다.The preparation method of (R, S) -6, 7-methylenedioxy-3-hydroxymethyl-1, 2, 3, 4-tetrahydro isoquinoline is as follows.

물(550cc)과 에탄올(550cc)에 용해시킨 (R, S)-6, 7-메틸렌디옥시-3-에톡시카보닐-1, 2, 3, 4-테트라하이드로 이소퀴놀린 염산염(115g)을 10-20℃의 온도로 유지하면서 에탄올(550cc)과 물(550cc)에 용해시킨 소디움 보로하이드라이드(71.5g)에 가하고, 이 혼합물을 20℃에서 30분간 교반한 후 3시간동안 환류하에 가열하고, 반응혼합물을 감압(25mmHg)하에 농축건조하여 잔사를 물(1,000cc)과 메틸렌클로라이드(500cc)에 용해시킨 다음, 불용성물질을 여과분리, 건조하고 여액을 경주(傾注)시킨 후 수성층을 메틸렌 클로라이드(총 600cc)로 3회 추출하여 합친 유기추출액을 탄산 칼리움상에서 건조시킨 다음에 감압(25mmHg)하에 농축건조시키면 생성물(융점 144℃)이 얻어진다. 다음, 이 고체와 여과하여 분리한 불용성 물질을 에틸아세테이트로부터 재결정시키면 (R, S)-6, 7-메틸렌디옥시-3-하이드록시메틸-1, 2, 3, 4-테트라하이드로 이소퀴놀린(49.9g)이 백색결정의 형태로 단리된다. 융점 144℃(R, S) -6, 7-methylenedioxy-3-ethoxycarbonyl-1, 2, 3, 4-tetrahydro isoquinoline hydrochloride (115 g) dissolved in water (550 cc) and ethanol (550 cc) It was added to sodium borohydride (71.5 g) dissolved in ethanol (550 cc) and water (550 cc) while maintaining the temperature at 10-20 DEG C. The mixture was stirred at 20 DEG C for 30 minutes and then heated under reflux for 3 hours. The reaction mixture was concentrated to dryness under reduced pressure (25 mmHg), and the residue was dissolved in water (1,000 cc) and methylene chloride (500 cc). The insoluble substance was filtered off, dried, the filtrate was raced, and the aqueous layer was methylene chloride. The combined organic extract was extracted three times (total 600 cc) and dried over kalium carbonate, and then concentrated to dryness under reduced pressure (25 mmHg) to obtain a product (melting point of 144 ° C). Then, the solid and the insoluble material separated by filtration were recrystallized from ethyl acetate to give (R, S) -6, 7-methylenedioxy-3-hydroxymethyl-1, 2, 3, 4-tetrahydro isoquinoline ( 49.9 g) is isolated in the form of white crystals. Melting point 144 ℃

(R, S)-6 ,7-메틸렌디옥시-3-에톡시카보닐-1, 2, 3, 4-테트라하이드로 이소퀴놀린의 염산염은 Chem. Pharm. Bun. 21, 2, 043(1973)에 발표된 H. Kato et al.의 방법에 따라 제조할 수 있다.The hydrochloride salt of (R, S) -6,7-methylenedioxy-3-ethoxycarbonyl-1, 2, 3, 4-tetrahydro isoquinoline is described in Chem. Pharm. Bun. 21, 2, 043 (1973), can be prepared according to the method of H. Kato et al.

[실시예 6]Example 6

6N 염산(20cc)에 용해시킨 (S)-3-하이드록시메틸-N-(이소퀴놀린-5-일)-1, 2, 3, 4-테트라하이드로 이소퀴놀린-2-카보티오아미드(1.3g)의 용액을 100℃에서 1시간동안 가열하여 냉각시킨 후 이 용액을 감압(40mmHg)하에 1/3의 용량으로 농축시키고 10N 수산화나트륨 수용액(5cc)을 가하여 알카리성화시킨 다음에 메틸렌 클로라이드(3×25cc)로 추출한 후 유기추출액을 합쳐 황산마그네슘상에서 건조시켜 여과후 여액을 40℃에서 감압(25mmHg)하에 농축건조시키면 (S)-3-(이소퀴놀-5-일이미노)-1, 5, 10, 10a-테트라하이드로 티아졸로[3, 4-b] 이소퀴놀린(0.8g)이 약한 베이지색결정의 형태로 얻어진다. 융점 164℃(S) -3-hydroxymethyl-N- (isoquinolin-5-yl) -1, 2, 3, 4-tetrahydro isoquinoline-2-carbothioamide (1.3 g) dissolved in 6N hydrochloric acid (20 cc) ) Was cooled by heating at 100 DEG C for 1 hour, and then concentrated under a reduced pressure (40 mmHg) to a volume of 1/3, alkalinized by adding 10 N aqueous sodium hydroxide solution (5 cc), followed by methylene chloride (3 x 25cc), and the organic extracts were combined, dried over magnesium sulfate, filtered, and the filtrate was concentrated to dryness under reduced pressure (25mmHg) at 40 ° C. (S) -3- (isoquinol-5-ylimino) -1, 5, 10, 10a-tetrahydro thiazolo [3,4-b] isoquinoline (0.8 g) is obtained in the form of weak beige crystals. Melting point 164 ℃

Figure kpo00011
=-197±2.5 (C =2, 클로로포름)
Figure kpo00011
= -197 ± 2.5 (C = 2, Chloroform)

출발물질로서 사용된 (S)-3-하이드록시메틸-N-(이소퀴놀-5-일-)-1, 2, 3, 4-테트라하이드로 이소퀴놀린-2-카보티오아미드의 제법은 다음과 같다.The preparation of (S) -3-hydroxymethyl-N- (isoquinol-5-yl-)-1, 2, 3, 4-tetrahydro isoquinoline-2-carbothioamide used as starting material is as follows. same.

에탄올(10cc)에 용해시킨 (S)-3-하이드록시메틸-1, 2, 3, 4-테드라하이드로 이소퀴놀린(0.82g)의 용액에 5-이소티오시아나토 이소퀴놀린(0.93g)을 가하고, 약 20℃에서 15시간동안 방치한 후 형성된 결정을 여과분리하고 에탄올로 세척하여 60℃에서 감압(0.1mmHg)하에 건조시키면 (S)-3-하이드록시메틸-N-(이소퀴놀-5-일)-1, 2, 3, 4-xp트라하이드로 이소퀴놀린-2-카보티오아미드(1.3g)가 얻어진다. 융점 190℃5-isothiocyanato isoquinoline (0.93 g) was added to a solution of (S) -3-hydroxymethyl-1, 2, 3, 4-tetrahydro isoquinoline (0.82 g) dissolved in ethanol (10 cc). After the mixture was left at about 20 ° C. for 15 hours, the formed crystals were separated by filtration, washed with ethanol, and dried under reduced pressure (0.1 mmHg) at 60 ° C. (S) -3-hydroxymethyl-N- (isoquinol-5). -Yl) -1, 2, 3, 4-xp trihydro isoquinoline-2-carbothioamide (1.3 g) is obtained. Melting point 190 ℃

5-이소티오시아나토퀴놀린의 제법은 다음과 같다.The preparation method of 5-isothiocyanatoquinoline is as follows.

피리딘(40cc)에 용해시킨 5-아미노 이소퀴놀(14.4g)의 용액을 약 -10℃의 온도로 유지하면서 피리딘(20cc)중 트리에틸아민(10.1g) 및 이황화탄소(40cc)의 용액에 적가하고, 이 온도에서 1시간후에 피리딘(20cc)에 용해시킨 N, N'-디싸이클로헥실카보디이미드(20.6g)의 용액을 적가하고 -10℃내지 20℃의 온도에서 3시간, 약 20℃에서 20시간동안 계속 교반시킨 후 형성된 N, N'-디싸이클로헥실티오우레아를 여과분리하여 메틸렌클로라이드(50cc)로 세척하고 여액을 40℃에서 감압(20mmHg)하에 증발건조한 다음, 고체잔사를 메틸렌 클로라이드(100cc)에 용해시켜 새로운 불용성 물질을 여과분리하고 메틸렌 클로라이드(30cc)로 세척 후 여액을 40℃에서 감압(20mmHg)하에 증발 건조시키고 잔사를 비등하는 아세토니트릴(100cc)에 용해시켜 냉각시킨 다음, 형성된 결정을 여과분리하여 디이소프로필 에테르(180cc)에 현탁시키고 약 20℃에서 30분간 교반한 후 불용성 물질을 제거하고 여액을 50℃에서 감압(20mmHg)하에 증발건조시켜 잔사를 아세토니트릴(40cc)로부터 재결정시키면 5-이소티오시아나토퀴놀린(5.9g)이 베이지색 결정성 고체로서 얻어지며(융점 99℃), 70℃에서 감압(1mmHg)하에 승화시키면 융점 102℃의 목적하는 화합물이 얻어진다.A solution of 5-amino isoquinol (14.4 g) dissolved in pyridine (40 cc) was added dropwise to a solution of triethylamine (10.1 g) and carbon disulfide (40 cc) in pyridine (20 cc) while maintaining the temperature at about -10 ° C. After 1 hour at this temperature, a solution of N, N'-dicyclohexylcarbodiimide (20.6 g) dissolved in pyridine (20 cc) was added dropwise, followed by 3 hours at -10 ° C to 20 ° C for about 20 ° C. After 20 hours of continuous stirring at N, N'-dicyclohexylthiourea was formed by filtration and washed with methylene chloride (50cc) and the filtrate was evaporated to dryness at 40 ℃ under reduced pressure (20mmHg), and then the solid residue was methylene chloride Dissolved in (100 cc), the new insoluble material was filtered off, washed with methylene chloride (30 cc), the filtrate was evaporated to dryness under reduced pressure (20 mmHg) at 40 ° C., dissolved in acetonitrile (100 cc) and boiled, and then cooled. Formed crystals were separated by filtration Suspend in isopropyl ether (180cc), stir at about 20 ° C for 30 minutes, remove insoluble material and evaporate the filtrate at 50 ° C under reduced pressure (20mmHg) to recrystallize the residue from acetonitrile (40cc) to give 5-isothio Cyanatoquinoline (5.9 g) is obtained as a beige crystalline solid (melting point 99 ° C.), and sublimation at 70 ° C. under reduced pressure (1 mmHg) affords the desired compound at melting point 102 ° C.

전술한 실시예들에서 출발물질을 적절히 선택함으로서 다음과 같은 일반식(I)형의 화합물을 얻을수 있다.By properly selecting the starting material in the above-described embodiments, a compound of formula (I) can be obtained.

(S)-9-니트로-3-(피리드-3-일이미노)-1, 5, 10, 10a-테트라하이드로 티아졸로-[3, 4-b] 이소퀴놀린 융점 44℃(S) -9-nitro-3- (pyrid-3-ylimino) -1, 5, 10, 10a-tetrahydro thiazolo- [3, 4-b] isoquinoline melting point 44 ° C

(R)-3-(이소퀴놀-5-일이미노)-1, 5, 10, 10a-테트라하이드로 티아졸로-[3, 4-b] 이소퀴놀린 융점 164℃(R) -3- (isoquinol-5-ylimino) -1, 5, 10, 10a-tetrahydro thiazolo- [3, 4-b] isoquinoline melting point 164 ° C

(S)-7-(클로로-3-(피리드-3-일이미노)-1, 5, 10, 10a-테트라하이드로 티아졸로-[3, 4-b] 이소퀴놀린 융점 125℃(S) -7- (chloro-3- (pyrid-3-ylimino) -1,5,10,10a-tetrahydro thiazolo- [3,4-b] isoquinoline melting point 125 ° C

(S)-7-플루오로-3-(피리드-3-일이미노)-1, 5, 10, 10a-테트라하이드로티아졸로-[3, 4-b] 이소퀴놀린 융점 99℃(S) -7-fluoro-3- (pyrid-3-ylimino) -1, 5, 10, 10a-tetrahydrothiazolo- [3, 4-b] isoquinoline melting point 99 ° C.

Claims (1)

일반식(Ⅱ)의 1, 2, 3, 4-테트라하이드로 이소퀴놀린 유도체를 환화시킴을 특징으로 하는 일반식(I)의 티아졸로[3, 4-b] 이소퀴놀린 유도체 및 그 산부가염의 제조방법.Preparation of thiazolo [3,4-b] isoquinoline derivatives of formula (I) and acid addition salts thereof, characterized by cyclization of 1, 2, 3, 4-tetrahydro isoquinoline derivatives of formula (II) Way.
Figure kpo00012
Figure kpo00012
식중 A 또는 A1은 3-피리딜 또는 5-이소퀴놀릴기를 표시하며; A 또는 A1가 3-피리딜기를 표시할 때, X1또는 X4는 수소 또는 할로겐원자를 표시하고, X2또는 X5는 수소 또는 불소원자를 표시하며, X3또는 X6는 수소원자 또는 니트로기를 표시하며, X1과 X2및 X3, 혹은 X4와 X5및 X6중의 적어도 2개는 수소원자를 표시하며, 또는 X1과 X2, X4와 혹은 X5는 함께 메틸렌디옥시기를 표시하고, X3또는 X6는 수소원자를 표시하며; A 또는 A1이 5-이소퀴놀릴기를 표시하면 X1, X2및 X3혹은 X4, X5및 X6는 각각 수소원자를 표시한다.Wherein A or A 1 represents a 3-pyridyl or 5-isoquinolyl group; When A or A 1 represents a 3-pyridyl group, X 1 or X 4 represents a hydrogen or halogen atom, X 2 or X 5 represents a hydrogen or fluorine atom, and X 3 or X 6 represents a hydrogen atom Or a nitro group, at least two of X 1 and X 2 and X 3 , or X 4 and X 5 and X 6 represent a hydrogen atom, or X 1 and X 2 , X 4 or X 5 together A methylenedioxy group is represented, X 3 or X 6 represents a hydrogen atom; When A or A 1 represents a 5-isoquinolyl group, X 1 , X 2 and X 3 or X 4 , X 5 and X 6 each represent a hydrogen atom.
KR7601892A 1976-08-05 1976-08-05 Preparation of thiazolo [3, 4-b] isoquinoline derivatives Expired KR800000304B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR7601892A KR800000304B1 (en) 1976-08-05 1976-08-05 Preparation of thiazolo [3, 4-b] isoquinoline derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR7601892A KR800000304B1 (en) 1976-08-05 1976-08-05 Preparation of thiazolo [3, 4-b] isoquinoline derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1019800000484A Division KR800000851B1 (en) 1980-02-07 1980-02-07 Process for preparing thiazolo(3,4-b)isoquinoline derivatives

Publications (1)

Publication Number Publication Date
KR800000304B1 true KR800000304B1 (en) 1980-04-14

Family

ID=19202545

Family Applications (1)

Application Number Title Priority Date Filing Date
KR7601892A Expired KR800000304B1 (en) 1976-08-05 1976-08-05 Preparation of thiazolo [3, 4-b] isoquinoline derivatives

Country Status (1)

Country Link
KR (1) KR800000304B1 (en)

Similar Documents

Publication Publication Date Title
CA1101430A (en) Derivatives of 4-amino 5-alkylsulphonyl ortho- anisamides, methods of preparing them
KR900007241B1 (en) Process for preparing bicyclic amino acids derivatives
JPH0737460B2 (en) Pyranoindolizine derivative and method for producing the same
US4605653A (en) 1-(hydroxymethyl)-1,6,7,11b-tetrahydro-2H,4H-[1,3]oxazino- or -thiazino-[4,3-a]isoquinoline derivatives and pharmaceutical compositions containing them
CA2104883A1 (en) Thienyl or pyrrolyl carboxylic derivatives; process for preparing the same and drugs containing them
KR880001283B1 (en) Process for preparing novel theophylline derivatives
JPH056542B2 (en)
US4064247A (en) Thiazolo[3,4-b]isoquinoline derivatives and pharmaceutical compositions containing them
JPS582948B2 (en) Kouvirus seitican 1 3-dimethyl-1H-pyrazolo (3,4D) quinoline Rui
KR800000304B1 (en) Preparation of thiazolo [3, 4-b] isoquinoline derivatives
US3530137A (en) Certain alkyl and aryl ethers and thioethers of tropine and derivatives thereof
FR2460934A1 (en) ISOQUINOLINE DERIVATIVES CONTAINING SULFUR, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
KR960014352B1 (en) Substituted tetrahydroisoquinoline compounds
US4002753A (en) 6-Substituted 3-carbethoxyhydrazinopyridazines
US3729477A (en) Certain 4-(3-amino-2-hydroxypropoxy)-1,2,5-thiadiazole-3-carboxamides
EP0138490B1 (en) 4-alkyl methylenedioxy-2-1[H]-quinazolinones
US4143143A (en) Substituted imidazo[5,1-a]isoquinolines
JP2875605B2 (en) 3-exomethylenepyrrolo [2,1-b] thiazole derivatives
RU2036924C1 (en) Method of synthesis of imidazo-(1,2-b)-pyridazine or their salts and imidazo-(1,2-b)-pyridazine derivatives or their salts
JPH04221386A (en) Novel derivative of 4h-pyrrolo(1,2-a)- thieno(2,3-f)(1,4)diazepine, preparation thereof, and pharmaceutical composition containing same
KR800000851B1 (en) Process for preparing thiazolo(3,4-b)isoquinoline derivatives
CS203934B2 (en) Process for preparing new derivatives of 1,3 thiazino/ /3,4-b/isoquinolines
US4108999A (en) Thiazolo[3,4-b]isoquinoline derivatives, pharmaceutical compositions containing them and pharmaceutical methods using them
EP0197533B1 (en) Dioxolobenzisoxazole derivatives and process for preparing the same
DK146129B (en) METHOD OF ANALOGY FOR THE PREPARATION OF ERGOPEPTIDALCALOID DERIVATIVES